Introduction

The advent of thoracoscopic surgery began over a hundred years ago when Dr. Jacobaeus, whilst working as a professor in internal medicine in Sweden, reported his initial experience using a thoracoscope in the diagnosis and treatment of pleural effusions (1). The majority of patients undergoing thoracoscopy at that time had tuberculosis. The development of medical anti-tuberculous medication made the use of thoracoscopy obsolete.

The discovery of fibre-optic light transmission and refinement of instruments led to a rejuvenation of the use of thoracoscopic surgery. In 1978 Miller et al. reported their experience using diagnostic thoracoscopy in previously undiagnosed thoracic disease (2). Alternative diagnostic modalities, available at the time, had failed to provide a diagnosis in every case. In a case series of 11 patients, thoracoscopy facilitated diagnosis in all without morbidity or mortality (2).

Traditional thoracoscope

The original thoracoscope consisted of a hollow tube with a small light bulb over the tip of the scope with a rheostat to control intensity. This resulted in a very limited and often poor view. The only person able to visualise the operative field was the operator. Available instruments were very limited.

Modern scopes

The use of video-assisted imaging systems revolutionised the function of thoracoscopy. In 1952, Fourestier, Gladu, and Valmiere developed a new imaging system which utilised a quartz rod to transmit an intense light beam distally along a telescope. The modern addition of computer chip television cameras further advanced the use of thoracoscopic surgery as it provided a means to project a magnified view of the operative field on to a monitor, freeing both the operating surgeon's hands, hence facilitating performance of complex procedures.

Further development of 30° and 45° angled viewing scopes has enabled better visualisation of the pleural cavity. Thus far surgeons have had to choose in advance which thoracoscope to use. This restricted their view of the surgical field and intra operative changes of thoracoscope were required to acquire a different viewing angle.

However, a thoracoscope with a variable viewing angle has now been developed. It allows the operator to adjust the viewing angle between 0° and 120° as required during the
Most authors recommend a 30 degree rigid telescope, a light source and cable, a camera and an image processor in order to perform video-assisted thoracoscopic surgery (VATS) (3,4). Recording facilities and a slave monitor are not essential but an added bonus. Appropriate theatre suites have now been developed. The thoracoscopes used can range in diameter from 3 to 10 mm, depending on the type of procedure being performed. The light source and cable used should also be appropriate for use in VATS. It is recommend that the light source used be an inert gas (e.g., Xenon) mediated “cold light” at 300 W or above. This is higher than that used in other file of minimally invasive surgery as blood in the operating field can absorb up to 50% of the light (5). The use of thinner fibre-optic cables resulted in improved transmission of light.

The invention of thoracoscopic instruments and modification of staplers to allow navigation around pulmonary vessels has led to a rapid increase in VATS procedures. Initially the instruments used in VATS were the same as those used in laparoscopic surgery. However, the increasing use of the VATS approach in thoracic surgery led to the development of tailor made instruments.

The technique

There is no single standardised operative technique in performing a VATS lobectomy. Current popular techniques use a utility incision and 0-3 ports. The original VATS lobectomies were performed using en-masse stapling of hilar structures (6). This approach however, is not recommended in support of individual isolation and ligation of hilar elements, as in open surgery due to oncological principles. VATS anatomical lobectomy for lung cancer was first described in 1992 (3).

Anterior approach

The anterior approach described by Hansen et al. utilises a 3 port technique (7). Both the surgeon and assistant stand on the anterior (abdominal) side of the patient with the surgeon positioned cranially. The approach uses a 10 mm 30° thoracoscope. In contrast to other published anterior approaches the utility incision is made first. It is placed directly over the hilum and the major pulmonary vessels between the breast and the inferior angle of the scapula in the fourth intercostal space anteriorly to the latissimus dorsi muscle (Figure 1).

The approach gives good access to the major vessels in case of major bleeding. Following inspection of the pleural cavity a low anterior 1 cm camera-port is positioned at the level of the top of the diaphragm and anterior to the level of the hilum and the phrenic nerve. Then a further 1.5 cm incision is positioned at the same level but more posterior in a straight line down from the scapula tip and anterior to the latissimus dorsi muscle. The sequence of dissection is the same for all lobes making it an easier technique to teach as both surgeon and assistant are positioned at the same side of the operating table. The first structures to be transected are the major vessels. To prevent air leaks there is minimal handling or dissection of the fissure. This is stapled with the visceral pleura remaining intact as a seal above the lung.

Figure 1 The three incisions made for the anterior approach forming a triangular configuration (8).
To facilitate a “no touch technique” the fissure stapling is performed quite late after the majority of the hilar structures have been taken care off.

Most surgeons use an anterior approach. This was popularised by the results published by McKenna Jr et al. (9). The group published a series of 1,100 cases. Their approach utilised 3 sometimes 4 ports. In this series the reported mortality was 0.8% and conversion to a thoracotomy occurred in 2.5% of cases.

Onaitis et al. published a large series on a two port VATS technique (10). Their series reported 500 cases with a surgical conversion rate of 1.6%, an operative and perioperative (30-day) mortality of 0% and 1%, respectively and a median hospital stay of three days.

The first published results on major pulmonary resections performed by a uniportal approach were published by Gonzalez et al. (11).

Posterior approach

The use of the posterior approach in performing a VATS lobectomy was first published by Walker et al. (12). The surgeon is positioned posteriorly to the patient (13). The utility incision is made in the 6th or 7th intercostal space anterior to latissimus dorsi muscle (Figure 2). The camera port is delivered in the auscultatory triangle and the approach utilizes a 0° thoracoscope rather than a 30°. The order of dissection is from posterior to anterior; the oblique fissure is developed first in order to identify and isolate pulmonary arterial branches.

The proposed benefit of the posterior approach is that it provides excellent visualization of the posterior aspect of the hilum facilitating dissection of the bronchi and branches of the pulmonary artery. The sequence of dissection in the posterior approach varies according to the lobe being removed. Furthermore in the posterior approach the tips of the instruments come towards the camera and are therefore easily seen.

Walker et al. published their initial experience having performed 158 cases via this approach (14). Their results showed a combined, inpatient and 30-day outpatient mortality of 1.8% with a conversion to open thoracotomy rate of 11.3%.

The evidence

Mortality and morbidity: open lobectomy

Two recently published large studies suggest that the mortality from open lobectomy is 1-2% with a morbidity of 32-37%.

The ACOSOG Z0030 is a prospective, multi-centre study involving 766 patients who underwent open lobectomy for early-stage non-small cell lung cancer (NSCLC), (T1N0 through T2N1) (15). The authors reported a mortality rate of 1% and an overall complication rate of 37%. However, these results reflect outcomes achieved in expert centres, with carefully selected patients.

Boffa et al. analysed data pertaining patients undergoing lobectomy for NSCLC from the Society of Thoracic Surgeons, database (16). This involved analysis of data on 6,042 patients operated on from 1999 to 2006. The reported mortality rate was 2% and the overall morbidity was 32%. This study included a very heterogeneous patient group.
population and is likely to represent current clinical care and are strikingly similar to the results of the ACOSOG Z0030 trial.

**Mortality and morbidity: video-assisted thoracoscopic lobectomy**

There are several studies reporting the peri operative outcomes following VATS lobectomy (9,10,17-19). The Cancer and Leukemia Group B 39802 trial was published in 2007 by Swanson et al. (17). This prospective, multicentre study was designed to assess the peri operative outcomes of 127 patients undergoing VATS lobectomy for early NSCLC. Peri operative mortality was 2.7%. Conversely, the peri operative morbidity rate was only 7.4%. However, this was a small group of highly selected patients.

In the largest series published to date McKenna et al. reported a 0.8% mortality rate with a morbidity rate of 15.3% (20). A systematic review conducted by Whitson et al. included 39 studies with 3,256 thoracotomy and 3,114 VATS patients. The authors found that VATS lobectomy was associated with a lower morbidity rate, a shorter chest tube duration and shorter length of hospital stay (21).

Data from several prospective and large retrospective studies also confirm that VATS lobectomy compares favourably with open lobectomy (10,14,20,22-26). The use of VATS reduces morbidity rates to 7.7-24.1% and mortality to 0.8-2.5%. The reported lower morbidity rates included shorter duration of air leak, lower incidence of post operative pneumonia and arrhythmias.

**Safety**

The initial concerns regarding the intra operative safety of VATS lobectomy have not born fruition. Flores et al. reported only 13 major intra operative complications having operated on 633 patients over 8 years (27).

Another similar series of 410 patients reported only three major intra operative complications requiring emergent conversion (28).

**Pain and quality of life**

Demmy et al. compared VATS vs. open lobectomy in patients with unfavourable risk factors (29). The authors reported that despite case matching VATS yielded shorter hospital stay (5.3±3.7 versus 12.2±11.1 days, P=0.02), shorter chest tube durations (4.0±2.8 versus 8.3±8.9 days, P=0.06), and earlier return to full preoperative activities (2.2±1.0 versus 3.6±1.0 months, P<0.01). The authors also noted that pain was noticeably better in the VATS group (none or mild, 63% versus 6%; severe, 6% versus 63%; P=0.01) at 3 weeks follow up.

Long et al. conducted a prospective randomised trial comparing quality of life after VATS vs. open lobectomy for clinically early stage NSCLC (30). They found that a month after operation both dyspnoea and pain score were significantly lower in the VATS group (10.9±7.4 vs. 17.4±9.6, P=0.047; 13.7±9.5 vs. 23.0±12.2, P=0.028).

A further prospective, non-randomized study involving 145 patients carried out by Andreetti et al. compared postoperative pain after a VATS lobectomy to a mini-thoracotomy approach (31). They found that the differences in pain scores were significant at 1, 12, 24 and 48 h postoperatively (6.24 vs. 8.74, 5.16 vs. 7.66, 4.19 vs. 6.89 and 2.23 vs. 5.33; P=0.000).

Furthermore, mean forced expiratory volume in 1 second and 6 minutes’ walk test values were better in the VATS group both at 48 h and 1 month following surgery.

Such observations were confirmed by Nagahiro et al. Their results showed faster and improved recovery rates of FVC, FEV1 and vital capacity with VATS lobectomy when compared with open lobectomy (32) at one and two weeks following surgery.

**Oncological validity**

Lymph node dissection is an essential part of any lung resection for lung cancer. Inadequate lymph node dissection results in inappropriate staging.

Both the National Comprehensive Cancer Network and The European Society of Thoracic Surgeons (ESTS) have developed comprehensive guidelines regarding adequate mediastinal lymphadenectomies (33).

There was though initial scepticism concerning the adequacy of lymph nodal dissection with VATS.

Studies so far though, have demonstrated comparable adequacy and operative mortality and morbidity with lymph node dissection when comparing VATS to open lobectomy (34).

A recent retrospective review of 770 patients with cN0-pN2 non-small lung cancer (VATS =450, open =320) by Watanabe et al. (35) looked at the total number of lymph nodes, nodal stations, mediastinal nodes and stations sampled during systematic lymph node dissection by VATS vs. open lobectomy. They observed no
differences in any of these four categories. These findings are further supported by the ACSOG Z0030 trial (n=752, VATS =66, open =686) were a similar number of LN and LN stations were assessed (36) regardless of technique employed.

**Competition with systemic/adjuvant therapy**

Petersen *et al.* conducted a study of patients who underwent anatomic resection (37). They specifically looked at whether a thoracoscopic lobectomy was associated with a higher rate of completion of adjuvant chemotherapy when compared to open lobectomy. They reviewed 100 consecutive patients with NSCLC who underwent lobectomy and received adjuvant chemotherapy. They analysed the time to initiation of chemotherapy, percentage of planned regimen received, number of delayed or reduced chemotherapy doses, toxicity grade, length of hospitalization, chest tube duration, 30-day mortality, and major complications. There were 43 patients in the thoracotomy group and 57 in the VATS group. All patients received a complete resection and there were no conversions. Patients who underwent thoracoscopic lobectomy had fewer delayed (18% versus 58%, P<0.001) and reduced (26% versus 49%, P=0.02) chemotherapy doses. A total of 61% of patients who underwent thoracoscopic resection received 75% or more of their planned adjuvant regimen without delayed or reduced doses compared to 40% in the open group (P=0.03).

**The immune response**

There have been four studies that have looked at the acute-phase reactants and cellular immune responses in patients who received VATS vs. open lobectomies. All four studies show that VATS lobectomy resulted in a lesser degree of inflammatory response (lower interleukin and C-reactive protein levels), reduced postoperative reduction in CD4 and natural killer cells, and reduced impairment of cellular cytotoxicity than open lobectomy (38-42). These results could explain the superiority of VATS lobectomy in morbidity and mortality in comparison with open lobectomy. It remains to be seen whether this difference in biological response translates to a superior long-term outcome.

**Cost effectiveness**

A study by Swanson *et al.* compared hospital costs and peri operative outcomes for VATS and open lobectomy procedures in the United States in 3,961 patients (43). Of these 2,907 underwent a lobectomy via open approach and 1,054 via a VATS approach. Hospital costs were higher for open versus VATS at $21,016 and $20,316 respectively (P=0.027).

These findings concur with the findings of Casali *et al.* They compared the costs of VATS and open lobectomy in 346 (93 VATS lobectomy, 253 thoracotomy) patients operated on between January 2004 and December 2006. The authors reported that the overall cost for a VATS lobectomy was $8,023±565 compared to the cost of an open lobectomy at $8,178±167 (P=0.0002). They found that although theatre costs for a VATS lobectomy were higher [€(2,533±230) versus €(1,280±54) for an open lobectomy (P=0.00001)] critical care and LOS were lower in the VATS group resulting in a net saving when performing a VATS lobectomy.

**European trends**

It is difficult to record the exact number of VATS cases being performed across Europe. However, the ESTS collated data from 235 units across Europe. The database has 56,656 recorded procedures with clinical information on more than 43,330 lung resections. Data analysis demonstrated that the number of VATS procedures dramatically increased from 10.7% between 2007-2009 to 18.8% between 2010-2012. Furthermore the VATS lobectomy rate increased from 2.7% to 11.3% between these two periods.

There is though a large variation in VATS practice across Europe. Several reasons might prevent units from embracing VATS surgery. These include, but are not limited to, overall Centre experience in VATS surgery, cost implications and initial capitol investment in instrumentation, cultural approach and trust to VATS surgery, theatre capacity and cancer target breaches and perceived complexity of the procedure.

Denmark has the highest VATS resection rate across Europe with 55% of lobectomies being performed via a VATS approach across the country in 2011. These cases are split between four specialist units performing between 100 and 325 lung cancer surgeries per annum.

The group in Copenhagen has the largest experience in Europe with more than 1,500 cases performed and 80% of procedures being carried out via VATS. Their experience is evidenced in literature (7,8,13-15).

Despite the fact that the first VATS lobectomy was
performed in Italy in October 1991 by Roviaro, the uptake of procedure has been relatively slow in Italy. Between then and December 2012 a total of 1,366 VATS lobectomies have been carried out in Italy. Twelve centers performed over 30 cases and only three centers performed over 100 cases.

In Norway and Sweden several VATS lobectomy programs have started but as yet no one single unit has performed over 100 cases. Similarly Germany, in recent survey of 39 respondents revealed a VATS resection rate of 10%, with all performed via the anterior approach. Two units have performed over 400 cases and seven over 100 cases.

There are 13 units in Austria of which 10 have established VATS lobectomy programs; 3 of these centers have performed over 100 cases (Spring 2013). In the majority of these centers VATS is performed by few surgeons. A total of 1,000 cases have been performed nationally with the VATS resection rate approaching 50% in active centers.

In Switzerland there are 9 public thoracic surgery centers and an unknown number of private centers. Only 2 of the public centers have done over 100 cases as most VATS lobectomy programs started in 2009 or later.

Of the 46 centers surveyed in Spain, 3 did not do VATS lobes, and 22 answered positively. Over 2,000 cases have been performed in total. These procedures were done either via a single port or 3 port approach. The first published results on major pulmonary resections performed by a uniportal approach come from Dr. Boffa et al. from Corunia, Spain (16).

In the Netherlands major centralization of thoracic surgery services and VATS programs began in 2006. One unit has performed over 500 cases and according to the Dutch lung cancer registry VATS lobectomies superseded open in 2012.

The data collated by the Society of Cardiothoracic Surgeons of Great Britain and Ireland shows that VATS resection rate has increased from 2% in 1993 to 14% in 2011. Data from the subsequent years is not yet published.

Conclusions

There is now enough body of evidence to suggest that VATS lobectomies offer a better outcome to cancer patients than open lobectomies. Selection remains the single most important factor to replicate results of studies. We are unlikely to be able to ethically justify a prospective, randomized comparison between open and VATS lobectomy.

This leaves us reliant on the best available current evidence. The current review confirms that VATS lobectomy is a superior procedure associated with lower peri operative morbidity and mortality than open lobectomy. It offers equivalent oncological results, is cost effective, and allows quicker return to social activitie.

Acknowledgements

Disclosure: The authors declare no conflict of interest.

References


